Tianjin Shengji

Tianjin Shengji Biopharmaceutical is a China-based biotechnology company focused on the research, development, and commercialization of recombinant protein therapeutics for metabolic disorders. The company specializes in the production of insulin analogues and GLP-1 receptor agonists, including biosimilar versions of insulin glargine, insulin lispro, and liraglutide. As a key subsidiary of Guizhou Shengjitang Pharmaceutical, Tianjin Shengji operates advanced manufacturing facilities that comply with GMP standards in the Tianjin Economic-Technological Development Area. Its products aim to provide high-quality, affordable treatment options for patients with diabetes in the Chinese market. The company continues to expand its pipeline with various insulin formulations and next-generation metabolic treatments to address the growing burden of endocrine diseases.